Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
82
resultados
Última actualización
16/10/2026 [07:09:00]
Resultados 25 a 50 de 82
Resumen de: KR20260140403A
본 발명은 3CLpro 단백질의 변이체와 야생형 3CLpro 저해제로 알려진 화합물과 상기 변이체의 결합 복합체, 이의 결정화 방법, 및 이의 3차원 결정체에 관한 것으로서, 본 발명의 변이체 및 복합체의 활성부위와 3차원 결정 구조 정보를 제공한다. 본 발명의 3CLpro 변이체의 결정은 결정화 정도가 우수하고 X-선 분석이 용이하다. 이에, 본 발명은 상기 변이체 또는 복합체를 이용한 신규 3CLpro 억제제 스크리닝 방법을 제공하며, 이를 통해 개발된 3CLpro 억제제는 항바이러스제로 이용될 수 있다. 본 발명의 3CLpro 변이체는 기존에 보고된 Sars-cov2 바이러스, 코로나바이러스, 인간 코로나 및 엔터로바이러스의 3CLpro와 다른 활성화 부위 및 결합부위를 가진다. 따라서 본 발명은 백신에 내성을 갖는 돌연변이 바이러스 감염 질환 치료제 내지는 기존에 보고된 치료제 보다 강력한 치료 효능을 나타내는 약물 개발 플랫폼으로 이용될 것으로 기대된다.
Resumen de: EP4810599A2
0001 The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).
Resumen de: EP4810861A2
An apparatus is used with supplied power for treating air in an environment. A housing is mobile in the environment and has an intake and an exhaust. At least one prime mover disposed in the housing between the intake and the exhaust is operable to move the air in the environment through the housing from the intake to the exhaust. At least one ultraviolet light source disposed in the housing is connected in electrical communication with the supplied power and is configured to generate ultraviolet radiation in at least one a portion of the housing through which the moved air passes from the intake to the exhaust. At least one permeable barrier disposed in the housing is configured to impede the moved air flow therethrough up to an impedance threshold. The at least one permeable barrier is connected in electrical communication to the supplied power and being heated to a surface temperature.
Resumen de: AU2025231994A1
The present invention relates to second-generation vaccine against COVID-19 to abrogate or diminish the binding of the SARS-CoV-2 spike (S) protein, or part of it, to the human angiotensin-converting enzyme 2 (hACE2). Such vaccines present several advantages as to avoid pathways of immune dysregulation activated following S protein/hACE2 interaction while maintaining the ability to elicit a strong and robust antibody neutralization response to SARS-CoV-2. The invention relates also to the use of the S protein for therapeutic uses and for vaccines in the prevention or treatment of SARS-CoV-2 infection or conditions or disorders resulting from such infection.
Resumen de: WO2026193026A1
The invention provides methods for determining if a subject suffering from SARS-CoV-2 infection is susceptible to developing fibromyalgia. Also provided herein are methods for identifying if a subject possesses a disease or condition characterized or caused by an immune system deficiency, such as chronic pain or fatigue, long COVID or interstitial cystitis (IC).
Resumen de: WO2026192998A1
A peptide that blocks the interaction of microtubule-associated factor End Binding protein 3 with inositol 1, 4, 5-trisphosphate receptor 3 and calcium release from the endoplasmic reticulum, and methods of using the peptide to treat a disease or condition, in particular an inflammatory disease or condition of the lung including sepsis, inflammatory lung injury, pulmonary fibrosis, acute respiratory distress syndrome, or SARS-CoV-2 infection.
Resumen de: US20260272861A1
Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.
Resumen de: US20260274133A1
Disclosed herein are systems for minimizing the risk of transmission of SARS-COV-2 and/or other infectious diseases between individuals in close proximity to one another. Said systems may comprise a substantially transparent shield component, a chamber component, and a suctioning component. The systems of the present disclosure are intended to remove any SARS-COV-2 virus and/or other infectious agents that may be travelling within aerosols.
Resumen de: WO2022098250A1
An object of the invention is a liposome preparation suitable for use in the treatment of COVID-19.
Resumen de: WO2026185415A1
The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the prophylactic or therapeutic treatment of an infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2.
Resumen de: US20260263473A1
In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.
Resumen de: US20260263430A1
The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
Resumen de: US20260266815A1
A system for viral monitoring in effluent includes at least one graphene-based field-effect transistor and circuitry, wherein the circuitry is configured to repeatedly monitor and determine presence of SARS-CoV-2 (COVID virus) in the effluent. The circuitry is configured to apply a gate voltage and measure a conductance across each of the at least one graphene-based field-effect transistor, compare the measured conductance across each of the at least one graphene-based field-effect transistor to a threshold conductance, and determine whether levels of the COVID virus exceed a predetermined threshold in the effluent. If levels of the COVID virus exceed the predetermined threshold in the effluent, the circuitry is configured to remove at least a portion of the bound COVID virus from the proteins of the at least one graphene-based field-effect transistor.
Resumen de: US20260263460A1
The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: US20260263587A1
The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-COV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-COV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-COV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-COV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-COV-2 Omicron mutant strain and subtype viruses thereof.
Resumen de: US20260263510A1
0000 A method of treating a COVID-19 infection including administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The particles of the composition are monodisperse, and spherical, and have an average diameter of 70-100 nanometers (nm).
Resumen de: US20260265825A1
0000 A signature for identifying a subject at risk of developing a severe reaction to a SARS-CoV virus by detecting one or more of elevated serum cytokines, reduced monocyte subclasses, differentially expressed genes in monocyte subclasses, differentially expressed gene in CD8+ effector memory T cells, and elevated chromatin accessibility in intermediate monocytes are disclosed herein. Also disclosed are methods for obtaining the signature, methods of identifying a subject at risk of developing a severe reaction to a SARS-CoV virus, and methods of treating COVID-19.
Resumen de: US20260263588A1
Polypeptides and nucleic acids encoding the polypeptides are provided that include severe acute respiratory syndrome Co-V-2 (SARS-CoV-2) spike polypeptide receptor-binding domain (RBD) polypeptides that include at least one non-naturally occurring N-linked glycosylation motif in any of the residues 369-372, 388-390, 405-407, 417-419, 437-441, 477-479, 487-489 and 501-503, which are capable of multimerization and thus presenting multiple copies of the RBD to enhance the immune response generated when the polypeptide is administered to a subject.
Resumen de: AU2025233025A1
Described herein are methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.
Resumen de: US20260265350A1
The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Resumen de: UA164235U
Method for preparing 4-(2-(difluoromethoxy)phenyl)-5-methylthiazol-2-amine: , which exhibits predicted activity against the SARS-CoV-2 virus, according to which a mixture of equimolar amounts of 2-bromo-1-(2-(difluoromethoxy)phenyl)propan-1-one and thiourea is boiled for three hours in propan-2-ol, cooled, filtered and suspended in 50 ml of saturated NaHCO3 solution, stirred for 5 hours, filtered, washed with water, crystallized from propan-2-ol.
Resumen de: WO2025080149A1
A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.
Resumen de: US20260259196A1
Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) from a subject that has been administered a an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus contains antibodies that inhibit influenza virus hemagglutinin (HA) glycoprotein hemagglutination activity, antibodies that neutralize SARS-COV-2 virus, antibodies that bind SARS-COV-2 spike protein, and/or antibodies that neutralize seasonal influenza virus. The methods include assaying a biological sample, where the biological sample is from a subject that has been administered an immunogenic composition directed to a seasonal influenza virus and an immunogenic composition directed to a SARS-COV-2 virus, and is not significantly affected by interference of analyte detection between the methods.
Resumen de: KR20260132653A
본 발명은 SARS-COV-2 바이러스 감염 질환의 중증도 예측용 바이오마커에 관한 것으로, SARS-COV-2 바이러스 감염 질환의 중증 환자 및 경증 환자에 대한 임상 데이터를 활용하여 cis-eQTM 분석을 통해 32종의 DNA 메틸화 마커 및 상기 DNA 메틸화 마커에 의해 차별적으로 발현되는 18종의 유전자 또는 단백질 마커를 제공한다.
Nº publicación: US20260259220A1 03/09/2026
Solicitante:
NOVAVAX INC [US]
NOVAVAX, INC.
Resumen de: US20260259220A1
0000 Disclosed are methods for detecting if a biological sample (e.g., saliva, serum, blood, plasma) contains IgA antibodies against SARS-CoV-2 S glycoproteins. The method includes contacting a biological sample with a SARS-CoV-2 S glycoprotein-coated surface, contacting the surface with a secondary antibody, and detecting the secondary antibody, where if a secondary antibody is detected, the sample contains IgA antibodies against the SARS-CoV-2 S glycoprotein. Assay substrates and kits for performing such methods are also disclosed.
BOPI
Sede Electrónica
